Summarized by Masters of Longevity from Frontiers - Health.
A narrative review synthesizes genetic, imaging, and mechanistic evidence linking elevated lipoprotein(a) to calcific aortic stenosis and surveys emerging Lp(a)-lowering therapies under clinical investigation.
Key Takeaways
- Genetic and epidemiological data support a causal role for elevated Lp(a) in initiating aortic valve calcification.
- Lp(a) promotes valve injury by carrying oxidized phospholipids and activating inflammatory and ATX–LPA osteogenic pathways.
- RNA-targeted drugs and oral assembly inhibitors can lower circulating Lp(a) by roughly 70% to over 95% in early trials.
